Supervisory Board appoints Thomas Borcholte as Chief Business Officer and member of the Executive Management Board of WILEX AG

Munich, 1 October 2007. The Supervisory Board of Munich-based biopharmaceutical company WILEX AG (ISIN DE0006614720/Frankfurt Stock Exchange/Prime Standard) today appointed Dr. Thomas Borcholte as member of the Executive Management Board and Chief Business Officer (CBO). Dr. Borcholte is responsible for Business Development and will implement the Company’s commercialisation strategy. He has over 20 years experience in leading positions in business development and marketing within the pharmaceutical and biotechnology industries. Most recently, Dr. Borcholte was Chief Marketing and Sales Officer at Topotarget S/A Copenhagen and member of the Executive Board of TopoTarget Germany AG, Frankfurt. He previously held positions at BIOGEN GmbH, Germany and Glaxo Wellcome GmbH, Hamburg. He graduated in biochemistry at the University of Hannover and received his PhD in human biology.

Dr. David Ebsworth, Chairman of the Supervisory Board of WILEX AG, commented: “Thomas Borcholte has extensive experience, expertise and an excellent network as well as an impressive track record in business development and marketing. The supervisory board is delighted that Dr. Borcholte has joined the Executive team.”

About WILEX AG
WILEX is a biopharmaceutical Company based in Munich founded in 1997 by a team of physicians and oncologists from the Technical University of Munich. WILEX is focused on the development of new cancer therapies based on antibodies and small molecules. The therapeutic approach of WILEX targets the prevention of growth, spread and the metastasis of malignant tumours and the destruction of malignant tumours in the body. The late stage multi-product portfolio includes both drug and medical product candidates ranging from research to late stage clinical development. Currently the following compounds are in clinical development: WX-G250 (development name: RENCAREX®), WX-671, WX-UK1 and CA9-SCAN. The Company’s strategy is to develop WILEX into a commercially successful biopharmaceutical Company with a broad portfolio of new drugs and medical products for the treatment of cancer. WILEX AG is listed on the Frankfurt Stock Exchange in the Official Market Segment (Amtlicher Markt) / Prime Standard.

ISIN DE0006614720
WKN 661472
Symbol WL6

Contact
Juliane Giese
Manager Public Relations
WILEX AG
Grillparzerstr. 10
81675 Munich
Germany
Tel.: +49 (0)89-41 31 38-29
Fax: +49 (0)89-41 31 38-99
email: investors@wilex.com
Website: http://www.wilex.com

Back to Archive